Dr. David Simpson, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- State University of New York at Buffalo School of Medicine (1979)
- Years since graduation
- 47
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 245
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1979Medical school: State University of New York at Buffalo School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NY license 147774
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Strong Memorial Hospital Rochester, NY
- Mount Sinai Hospital New York, NY
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 245
- Services billed
- 1,257
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 196 | 144 |
| Established patient office or other outpatient visit, 30-39 minutes | 174 | 120 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 71 | 58 |
| New patient office or other outpatient visit, 60-74 minutes | 66 | 66 |
| Needle measurement of electrical activity in arm or leg muscles, limited study | 64 | 45 |
| Nerve conduction, 13 or more studies | 58 | 58 |
| Telephone medical discussion with physician, 21-30 minutes | 51 | 36 |
| Ultrasonic guidance for needle placement | 42 | 20 |
| Electrical stimulation for guidance with injection of chemical for paralysis of nerve muscle | 41 | 20 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 29 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pregabalin Other prescribers in New York, NY | 149 |
| Gabapentin Other prescribers in New York, NY | 64 |
| Duloxetine Hcl Other prescribers in New York, NY | 56 |
| Prednisone Other prescribers in New York, NY | 28 |
| Propranolol Hcl Er (propranolol hcl) Other prescribers in New York, NY | 18 |
| Octagam (immun globg(igg)/malt/iga ov50) | 15 |
| Primidone Other prescribers in New York, NY | 15 |
| Gammagard Liquid (immun glob g(igg)/gly/iga ov50) | 13 |
| Pyridostigmine Bromide Other prescribers in New York, NY | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 56 payments worth $41,507 in total to this clinician.
| Grt US Holding, Inc. | $16,150 |
|---|---|
| Vertex Pharmaceuticals Incorporated | $11,713 |
| Argenx US, Inc. | $7,376 |
| AbbVie Inc. | $2,658 |
| Tris Pharma Inc | $2,000 |
| Ipsen Pharma Sas | $750 |
| Merz Pharmaceuticals, LLC | $475 |
| Janssen Scientific Affairs, LLC | $298 |
| Consulting Fee | $17,976 |
|---|---|
| Travel and Lodging | $11,742 |
| Honoraria | $10,000 |
| Food and Beverage | $1,789 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Grt US Holding, Inc. Jun 16, 2025 | Honoraria | $10,000 |
| Grt US Holding, Inc. Apr 30, 2025 | Travel and Lodging travel to SANTIAGO, Chile · in-kind | $6,000 |
| Vertex Pharmaceuticals Incorporated Jul 16, 2025 | Consulting Fee | $5,940 |
| Vertex Pharmaceuticals Incorporated Mar 19, 2025 | Consulting Fee | $3,280 |
| Argenx US, Inc. Nov 20, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to San Francisco, CA | $2,813 |
| Argenx US, Inc. Nov 20, 2025 | Consulting Fee VYVGART HYTRULO · Neurology | $2,500 |
| Tris Pharma Inc Aug 27, 2025 | Consulting Fee | $2,000 |
| Argenx US, Inc. Jul 25, 2025 | Consulting Fee | $1,406 |
| AbbVie Inc. Sep 17, 2025 | Consulting Fee | $1,200 |
| AbbVie Inc. Mar 24, 2025 | Consulting Fee | $900 |
All 26 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Argenx US, Inc. Dec 3, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to San Francisco, CA | $85.79 |
| Argenx US, Inc. Dec 3, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to San Francisco, CA | $78.14 |
| Argenx US, Inc. Dec 3, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to San Francisco, CA | $73.49 |
| Argenx US, Inc. Nov 20, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to San Francisco, CA | $2,813 |
| Argenx US, Inc. Nov 20, 2025 | Consulting Fee VYVGART HYTRULO · Neurology | $2,500 |
| AbbVie Inc. Sep 17, 2025 | Consulting Fee | $1,200 |
| Merz Pharmaceuticals, LLC Sep 15, 2025 | Travel and Lodging Xeomin · Musculoskeletal · travel to Frankfurt, Germany · in-kind | $39.69 |
| Merz Pharmaceuticals, LLC Sep 15, 2025 | Travel and Lodging Xeomin · Musculoskeletal · travel to Frankfurt, Germany · in-kind | $36.31 |
| Tris Pharma Inc Aug 27, 2025 | Consulting Fee | $2,000 |
| Argenx US, Inc. Jul 25, 2025 | Consulting Fee | $1,406 |
| Vertex Pharmaceuticals Incorporated Jul 16, 2025 | Consulting Fee | $5,940 |
| Vertex Pharmaceuticals Incorporated Jul 16, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $138 |
| Grt US Holding, Inc. Jun 16, 2025 | Honoraria | $10,000 |
| Ipsen Pharma Sas May 13, 2025 | Consulting Fee Dysport · Neurology | $750 |
| Grt US Holding, Inc. Apr 30, 2025 | Travel and Lodging travel to SANTIAGO, Chile · in-kind | $6,000 |
| Grt US Holding, Inc. Apr 30, 2025 | Travel and Lodging travel to SANTIAGO, Chile · in-kind | $150 |
| AbbVie Inc. Mar 24, 2025 | Consulting Fee | $900 |
| Vertex Pharmaceuticals Incorporated Mar 19, 2025 | Consulting Fee | $3,280 |
| Vertex Pharmaceuticals Incorporated Mar 15, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $776 |
| Vertex Pharmaceuticals Incorporated Mar 10, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $348 |
| Vertex Pharmaceuticals Incorporated Mar 10, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $84.70 |
| Vertex Pharmaceuticals Incorporated Mar 10, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $74.54 |
| Vertex Pharmaceuticals Incorporated Mar 9, 2025 | Travel and Lodging JOURNAVX · PAIN · travel to BOSTON, MA · in-kind | $322 |
| AbbVie Inc. Feb 6, 2025 | Travel and Lodging travel to IRVINE, CA · in-kind Company’s descriptionM25-076 | $253 |
| Vertex Pharmaceuticals Incorporated Jan 11, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $207 |
| Vertex Pharmaceuticals Incorporated Jan 10, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $262 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $10,650 in research payments for these studies, mostly to the institutions running them.
- Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor
AbbVie Inc. · Completed · NCT05216250 - Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adu…
Merz Pharmaceuticals, LLC - A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
Ipsen Pharma Sas · Completed · NCT04936542
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.